Clinical lung cancer · 2026
Low Baseline Absolute Neutrophil Count and Chemotherapy Safety in African American Patients with Advanced Lung Cancer: A Retrospective Cohort Study.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Lalla Mumtu, Du Simo, Gor Rajvi, Narvel Hiba, D'Aiello Angelica, Shivakumar Jeevan, Yusuf Hasiya, Maia Catarina Martins, Beumer Jan H, Cheng Haiying
Аннотация
INTRODUCTION: African American patients remain underrepresented in cancer clinical trials, and minimum absolute neutrophil count (ANC) eligibility thresholds may disproportionately exclude individuals with Duffy-null associated neutrophil count (DANC), a common biologic variant associated with lower baseline ANC and no clearly increased infection risk. We evaluated whether African American patients with advanced lung cancer and lower baseline ANC experience greater chemotherapy-related complications.
METHODS: We conducted a retrospective cohort study of African American patients with stage IV lung cancer receiving first-line chemotherapy at a single center. Patients were grouped by baseline ANC (≤ 2500 vs. > 2500 cells/µL) as a pragmatic proxy for potential DANC. We collected demographic, clinical, and ANC data at baseline, end of cycle 1, and nadir during the first 4 chemotherapy cycles, comparing infectious complications, febrile neutropenia, antibiotic and growth factor use, and dose modifications between the groups.
RESULTS: Among 127 eligible patients, 9 (7.1%) had baseline ANC ≤ 2500 cells/μL. These patients had more severe post-treatment neutropenia (P = .004) and a lower median ANC nadir (P = .05) compared to those with baseline ANC > 2500 cells/µL. No significant differences were observed in infection rates, febrile neutropenia, antibiotic use, or growth factor use.
CONCLUSION: Lower baseline ANC was associated with greater neutropenia severity but not increased infectious complications in African American patients with advanced lung cancer. These findings suggest uniform ANC-based eligibility thresholds merit reconsideration, supporting prospective studies incorporating Duffy status to promote equitable trial eligibility and toxicity management.
METHODS: We conducted a retrospective cohort study of African American patients with stage IV lung cancer receiving first-line chemotherapy at a single center. Patients were grouped by baseline ANC (≤ 2500 vs. > 2500 cells/µL) as a pragmatic proxy for potential DANC. We collected demographic, clinical, and ANC data at baseline, end of cycle 1, and nadir during the first 4 chemotherapy cycles, comparing infectious complications, febrile neutropenia, antibiotic and growth factor use, and dose modifications between the groups.
RESULTS: Among 127 eligible patients, 9 (7.1%) had baseline ANC ≤ 2500 cells/μL. These patients had more severe post-treatment neutropenia (P = .004) and a lower median ANC nadir (P = .05) compared to those with baseline ANC > 2500 cells/µL. No significant differences were observed in infection rates, febrile neutropenia, antibiotic use, or growth factor use.
CONCLUSION: Lower baseline ANC was associated with greater neutropenia severity but not increased infectious complications in African American patients with advanced lung cancer. These findings suggest uniform ANC-based eligibility thresholds merit reconsideration, supporting prospective studies incorporating Duffy status to promote equitable trial eligibility and toxicity management.